DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity.

TitleDNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity.
Publication TypeJournal Article
Year of Publication2017
AuthorsVanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond JM, Schneider RJ, Inghirami G, C Coleman N, Formenti SC, Demaria S
JournalNat Commun
Volume8
Pagination15618
Date Published2017 06 09
ISSN2041-1723
KeywordsAnimals, Basic-Leucine Zipper Transcription Factors, CD8-Positive T-Lymphocytes, Cell Line, Tumor, CTLA-4 Antigen, Dendritic Cells, Exodeoxyribonucleases, Female, Gene Expression Regulation, HEK293 Cells, Humans, Immunotherapy, Interferon-beta, Mammary Neoplasms, Animal, Membrane Proteins, Mice, Mice, Inbred BALB C, Mice, Inbred C57BL, Mice, Inbred NOD, Mice, Knockout, Mice, SCID, Neoplasms, Nucleotidyltransferases, Phosphoproteins, Receptor, Interferon alpha-beta, Repressor Proteins
Abstract

Radiotherapy is under investigation for its ability to enhance responses to immunotherapy. However, the mechanisms by which radiation induces anti-tumour T cells remain unclear. We show that the DNA exonuclease Trex1 is induced by radiation doses above 12-18 Gy in different cancer cells, and attenuates their immunogenicity by degrading DNA that accumulates in the cytosol upon radiation. Cytosolic DNA stimulates secretion of interferon-β by cancer cells following activation of the DNA sensor cGAS and its downstream effector STING. Repeated irradiation at doses that do not induce Trex1 amplifies interferon-β production, resulting in recruitment and activation of Batf3-dependent dendritic cells. This effect is essential for priming of CD8 T cells that mediate systemic tumour rejection (abscopal effect) in the context of immune checkpoint blockade. Thus, Trex1 is an upstream regulator of radiation-driven anti-tumour immunity. Trex1 induction may guide the selection of radiation dose and fractionation in patients treated with immunotherapy.

DOI10.1038/ncomms15618
Alternate JournalNat Commun
PubMed ID28598415
PubMed Central IDPMC5472757
Grant ListUL1 TR001445 / TR / NCATS NIH HHS / United States
P30 CA016087 / CA / NCI NIH HHS / United States
R01 CA201246 / CA / NCI NIH HHS / United States
UL1 TR000038 / TR / NCATS NIH HHS / United States
S10 RR027619 / RR / NCRR NIH HHS / United States
Related Faculty: 
Giorgio Inghirami, M.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700